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Abstract
The research outcomes reported throughout this thesis provides a novel contribution to the de-
velopment of CeO2 NPs as a radioprotection adjuvant to radiotherapy. The development of an
in-vitro model enabled investigations of the biocompatibility of nanoceria and its subsequent ef-
ficacy to provide radiation protection to cells exposed with X-ray radiation sources.
The characterisation of the nanoceria sample manufactured within the TNT collaboration at
UOW confirms the presence of the CeO2 phase. The CeO2 phase is known to inherit mixed va-
lency states that are responsible for the reported antioxidant characteristics. It is shown that CeO2
NPs are biocompatible and non-toxic to 9L and MDCK cells at concentrations up to 50 µg/ml.
The viability of 9L and MDCK cells is significantly reduced as the concentration is increased,
suggesting that CeO2 NPs exhibit a toxicity which is concentration dependent.
An energy-dependent radioprotection efficacy is uncovered for malignant (9L) cells exposed to
CeO2 NPs and irradiated using 10 MV and 150 kVp X-rays, which may be driven by the high-Z
atoms contained within the material’s composition. Radioprotection is conferred at megavoltage
energies with a deduced PER value of 1.230 ± 0.003. Interestingly, a transformation occurs
when irradiating cells at 150 kVp, where the significant protection observed dissipates following
the shift in treatment beam quality. A complex counterbalancing mechanism of sensitisation and
enhancement can explain the observed transformation. Competing processes that may contribute
to the energy dependent radioprotection of CeO2 NPs includes high-LET Auger electron pro-
duction, characteristic X-rays and free-radical scavenging. The presence of high-LET damage is
indicated at the 150 kVp energy through the increase of the survival curve linearity, suggesting a
localised change in radiation quality and relative biological effectiveness.
Pilot studies investigating the radioprotective efficacy of CeO2 NPs on non-malignant (MDCK)
cells indicate similar trends of energy dependent radioprotective characteristics.
The research described within this thesis demonstrates the importance of considering high-Z
effects, particularly in the development of CeO2 NPs as a clinical radioprotector throughout ra-
diotherapy. It is clear that vast amounts of work is required to comprehensively develop CeO2
NPs as a radiation protection adjuvant to radiotherapy.
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Chapter 1
Introduction
1.1 Objectives and Overview of this Thesis
Radiotherapy is an effective tool commonly used for the control of malignant tumours. Maximis-
ing the probability of tumour control and eradication of malignant cells requires high doses of
ionising radiation, which can exceed the tolerability of normal, non-malignant tissues and cells.
Innovative techniques and treatment modalities attempt to minimise these adverse side effects.
Common approaches include the use of conformal, intensity modulated and volumetric modu-
lated arc treatments coupled with carefully planned fractionation schemes. To optimise radiation
therapies, synergistic drugs such as amifostine have been used [1]. The development of new and
improved drugs using mechanisms similar to amifostine is under widespread development and
could pave the way of the future of radiation therapies.
The application of cerium oxide nanoparticles in the field of radiation protection can offer a new
alternative to the only current clinically used radioprotector amifostine. The similarity between
the two materials lies within their mechanism to provide radioprotection i.e. free-radical scav-
enging. There are many avenues requiring development and further understanding to establish
cerium oxide nanoparticles (CeO2 NPs) as a promising radioprotector for use throughout radio-
therapy.
Many studies have utilised cerium oxide nanoparticles both in-vitro and in-vivo to characterise its
toxicity to cells and also to investigate its ability to provide radiation protection through the pro-
cess of scavenging free radicals. Throughout the literature, it is evident that further development
is essential. The contribution of the TNT collaboration is to further develop the use of CeO2 NPs
as a radiation protection agent, with a focus on the factors that affect its overall efficacy using
in-vitro models.
There are two main properties of CeO2 NPs that are of particular interest throughout the initial
development, including the efficacy of radioprotection across a range of clinically relevant treat-
1
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ment energies and also the differences that may occur between cell types.
In an attempt to further develop the use of CeO2 NPs in their radiation protection application, a
variety of experimental investigations have been implemented with a focus on determining the
degree and efficacy of the radiation protection provided by CeO2 NPs synthesised at UoW. Two
cell lines - 9L, a gliosarcoma malignant rat brain tumour cell and MDCK, non-malignant canine
kidney cells were utilised to test for any changes in efficacy at different treatment energies and
also between the two cell types at a given energy. In addition to understanding the functionality
of CeO2 NPs and their ability to provide radiation protection, the material was characterised to
gain insight and understand its structure, size and morphology. Subsequently, the biocompatibil-
ity of the material was investigated to clarify the ambiguity surrounding the toxicity CeO2 NPs.
The above approach is essential to the successful development of novel compounds and drugs
that can be clinically applied and used, particularly throughout radiotherapy.
In this thesis, the hypothesis is that the efficacy of CeO2 NPs to act as a radioprotector may be
dependent on the energy of X-rays used during radiation treatments. Investigations testing this
hypothesis in the TNT collaboration with the Prince of Wales Hospital resulted in the use of two
different beam qualities - 150 kVp and 10 MV X-rays. In an attempt to add weight to this hypoth-
esis, a radioresistant (9L) cell line was implemented as the primary test subject. Furthermore,
non-malignant cells (i.e. MDCK cell line) were tested as a part of a pilot study, investigating any
change in efficacy of the NP to provide radioprotection for different cell types i.e. malignant vs.
non-malignant.
The clonogenic cell survival technique is used to qualitatively and quantitatively measure the
efficacy of CeO2 NPs to provide radiation protection. The cell survival approach enables any
changes in radiobiological characteristics such as radiosensitivity to be measured. Alternative
techniques such as the MTT assay only detect changes in metabolic activity and cannot provide
information on radiobiological influence of CeO2 NPs.
Experimental investigations uncover a change in the efficacy of CeO2 NPs to function as ra-
dioprotectors. The change in efficacy varies with the treatment energy used due to the high-Z
component of CeO2 NPs. The radioprotection that CeO2 NPs provide is achieved by scavenging
free radicals that are produced during the radiolysis of water - the indirect pathway of radiation
damage [2]. The presence of the high-Z atoms contained within CeO2 are responsible for an
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increased probability and production of lethally damaging, low energy secondary electrons that
have the potential to produce clusters of free radicals. At lower X-ray energies, the influence of
these high-Z components becomes more pronounced, contributing to the direct damage effects
that we observe throughout the kilovoltage X-ray treatments. Preliminary studies using MDCK
cells exposed to CeO2 NPs show similar trends with changes in treatment energy, however the
presence of CeO2 NPs has a less dramatic influence to MDCK cells in comparison to 9L cells.
The phenomenon should be further investigated although cellular characteristics such as struc-
ture, radiosensitivity and origin can account for the variability shown.
The following sections of this thesis cover the above outlined study in an ordered and detailed
manner. The structure and content of the thesis includes:
• Chapter 2 - Literature review
The literature review is a comprehensive summary of the literature and work that has been
published. This review is used to guide and inform the direction of the research that has
been undertaken.
• Chapter 3 - Materials and methodology
The methods and materials section is used to inform the reader with details of the materials
which have been used and how these materials have been used to perform the work that
has been undertaken.
• Chapter 4 - Results
The results section is where all of the collated work and data is presented to the reader in a
logical and concise manner.
• Chapter 5 - Discussion
The discussion is an evaluation of the reported results with an analysis of how it can con-
tribute to the existing literature, while comparing to similar work that has been published.
• Chapter 6 - Conclusions and future directions
The conclusion is a summary of the all the work performed, how it can be used and an
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extension to further studies that can be performed to assist the overall development of
CeO2 NPs as a radioprotector.
Chapter 2
Literature Review
Radiotherapy is a technique that has been widely adopted as a medical intervention to aid in the
treatment and curing process for a range of malignant tumours – more broadly and commonly
reffered to as cancer. Conventional X-ray and γ-ray radiotherapy is the most common and widely
used radiation modality for the treatment of malignant disease. With the forecast of a rise in the
incidence rate of cancers reaching 15 million new cases annually, continued development of
radiotherapy techniques are essential [3]. The implications associated with the erradication of
deep-seated tumour volumes is the impact on the surrounding healthy tissues and their limited
tolerances to these ionising radiations. Subsequently, the development of novel radioprotectants
with the potential to minimise radiation-induced normal tissue damage can revolutionise current
treatment protocols and patient outcomes in a positive way.
The following review illustrates the areas of current research using CeO2 NPs, highlighting both
the importance and need for our research and how it can contribute to the development of CeO2
NPs in its applications as a radioprotector.
2.1 Pathways of radiation-induced cellular damage & current
clinical radioprotectors
A thorough understanding of the mechanisms that result in radiation-induced cellular damage is
an essential component in the effective development of novel approaches advancing radiother-
apy practices. Ionising radiation incident on a medium initiates a series of reactions that deposit
energy along the ionising particles trajectory. The cross-sections for interactions with matter,
including – photoelectric, compton and pair production, all have varying dependencies on the
atomic number (Z) of the absorbing medium. The low-Z nature of human tissues places greatest
dependence on compton interactions where secondary electrons are generated, leading to ionisa-
tion and excitation within the absorbing medium causing cellular damage.
5
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Two main pathways of radiation-induced damage exist – indirect and direct effects (Figure
2.1) [2]. In the field of low-LET radiations, indirect damage is the most probable mode of
cellular damage which is, in part, due to the composition of the body – approximately 70 %
water. In the field of ionising radiation, water molecules are disrupted in a process known as the
radiolysis of water, where the dissociation of water molecules creates hydroxide and other free
radicals. Free radicals such as the hydroxide radical inherit large chemical reactivity that has the
ability to cause molecular alterations and disrupt the structure of DNA.
The alternative process to indirect damage (i.e. direct damage) occurs most commonly in the
field of high-LET radiations. The process of direct damage is linked to the photoelectric effect
where an incident photon is completely absorbed by an atom within the medium, ejecting an
atomic electron that can directly interact with DNA molecules (Figure 2.1) [4]. In the field of
high-LET secondary particles, clustered damage commonly results in irreparable double strand
breaks (DSB). The presence of dense and clustered ionisations that induce DSBs result in charac-
teristic linear-shaped cell survival curves, where DNA repair mechanisms often prove inadequate
to overcome the induced damage.
All biological and cellular environments inherit a residual level of reactive oxygen species (ROS)
that are essential for normal routine biological function. The residual level of ROS is con-
trolled and maintained by cellular protective molecules and proteins such as metallothionine,
glutathione, catalase and superoxide dismutase (SOD) [5]. Indirect and direct radiation-induced
damage creates an increased level of ROS above residual levels, resulting in oxidative stress [6,7].
A reduction in the excess ROS is a current approach used to overcome radiation-induced oxida-
tive stress and damage.
Amifostine, a current and clinical radioprotector utilises a free-radical scavenging approach to
reduce excess ROS levels [1, 8, 9]. The limitations associated with the use amifostine includes
its cost, toxicity, dosing requirements and its inability to be used in conjunction with chemother-
apy [10, 11]. Furthermore, radioprotectors are generally designed to reduce the early effects of
radiation such as nausea, fatigue, mucositis, hair loss and erythema. Hensley et al (2009) report
in the clinical practice guidelines for clinical oncology that the routine use of amifostine for the
prevention of mucositis is not supported for head and neck radiotherapy [11]. It is evident that
there is a need for the development of novel radiation protection “drugs” that incorporate mini-
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Figure 2.1 The two main mechanisms of DNA damage upon exposure to ionising radiation include indi-
rect and direct damage. Direct damages involve the process of ejecting secondary electrons that directly
create DNA strand breaks. Indirect damage occurs when secondary electrons dissociate water molecules,
releasing free-radicals that create scissions in DNA molecules.
mal (if any) side effects across a broad spectrum of sites – vastly improving the current radiation
protection market.
2.2 Quantitative interpretation of the cell survival response
following exposure to ionising radiation
An important aspect of any experimental radiobiological study is to consistently analyse and pro-
vide an interpretation of experimental findings. It is difficult with a single experimental technique
(or assay) to isolate individual physical, chemical and molecular processes that may contribute
to a given response. Application of mathematical models to cell survival relationships sets up
a common framework where the wider scientific community can compile data and construct
evidence-based theories of cell survival responses. The endpoint of any radiobiological study is
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to maximise the therapeutic index of current techniques, which can be aided through mathemat-
ical modelling and statistical analysis. Mathematical modelling may help isolate mechanisms
for further investigation in our journey to reach the ideal endpoint - maximising the therapeutic
index.
There are many empirical models that have been developed to provide a mathematical fit of ex-
perimental data. Development of various models has resulted in an ability to begin providing a
physical/mechanistic interpretation of the cellular response of a given therapy. The models which
can be incorporated into an in-vitro cell survival study include the linear-quadratic (LQ) model,
lethal-potentially lethal damage model, repair saturation model, linear-quadratic-cubic model,
low-dose hypersensitivity model, tumour control probability (TCP) model and the normal tissue
complication probability (NTCP) model, among others [12–21].
The aforementioned models all have their own merits for their use in modelling cell survival
response. The purpose of this study was to qualitatively and quantitatively observe and analyse
the response of in-vitro cell cultures to X-ray radiation in the presence and absence of CeO2 NPs.
A comparison of cell survival models was not a part of this study however, an awareness of the
available models was considered to assess the aplicability and practicality of the LQ model for
use throughout this study.
The choice of the LQ model was aided by ease of implementation, good agreement for spare-
sely ionising radiation (i.e. kV-MV X-rays), applicable for the dose ranges explored throughout
this study (i.e. 0 – 8 Gy), widespread use in cell survival modelling and the wealth of α and β
data for a large variety of cell lines. Contribution towards existing and available data enables
collaborations and comparisons with the wider scientific community in an effort to maximise the
therapeutic index of radiation therapy. It should be acknowledged that any model has its own
limitations and should be interpreted with care. It is known that the LQ model is not correct for
very low doses i.e. less than 0.5 Gy, and thus, intepretation in the low dose range is considered
unreliable [22].
The cell surviving fraction (SF), expressed as a function of dose (D), can be described by the
linear-quadratic model as shown in equation 2.1.
S = exp(−αD)× exp(−βD2) = exp[−(αD + βD2)] (2.1)
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The two constants, α and β, provide a quantitative interpretation of the cells response across a
range of absorbed doses. Equation 2.1 demonstrates that there are two key components to the
model - a linear component and a quadratic component. Conveniently, α and β have been linked
to biological responses and characteristics of a given cell type to the applied therapy [2]. The
linear component, α, has been interpreted as a marker of cellular radiosensitivity as α affects
the initial slope and degree of linearity of the cell survival curve i.e. single-hit damage [2, 23].
The quadratic component, β, is widely interpreted as a multi-hit damage component which is
highlighted as an increase in the shouldered appearance of the cell survival curve [2, 12, 23, 24].
Interestingly, Fertil et al (1985) and Tubiana et al (1990) discuss β in reference to the repair
capacity of cells in response to radiation-induced damage. Fertil et al (1985) analysed a com-
pilation of 101 cell survival curves and concluded that there exists an inverse proportionality
between α and β i.e. low α-value is associated with a high β-value, highlighting that α and β
do not change in isolation [23]. Consequently, an effective radioprotectant could be indicated
through a reduction in the cellular radiosensitivity i.e. lower α-value, which would otherwise be
coupled with a corresponding increase in β and a more shouldered cell survival response.
The significant knowledge base surrounding cell survival analysis, particularly with the LQ
model, enables researchers around the world to make educated interpretations of the potential
physical and biological effects that may occur in response to the given therapy.
2.3 Nanomedicine: bimodal approaches in radiotherapy
The development of new and innovative approaches to further optimise radiation therapies is a
subject of great scientific and medical interest. In particular, adjuvants to radiotherapy are cur-
rently being developed and tested for their abilities to optimise certain aspects of radiotherapy
including: localised dose enhancement, radiation protection and the efficacy of immunological
toxins (i.e. chemotherapy).
Bimodal approaches using nanoparticles have the potential to revolutionise radiotherapy and the
fight against cancer. Nanotechnology has undergone significant expansion with applications ex-
tending into biology and medicine. The size of nanomaterials (i.e. ≤ 100 nm) and their unique
and reactive surface chemistry makes them an attractive adjuvant to radiotherapy. The surface
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Figure 2.2 The surface area to volume ratio follows an inverse proportionality with particle radius, show-
ing that nanoparticles have large surface areas per unit mass. The surface reactivity is subsequently max-
imised by using smallest size nanoparticles [25].
area to volume ratio follows an inverse proportionality with particle radius, supporting the notion
that smaller materials (i.e. nanomaterials) have an increasing surface reactivity (Figure 2.2).
Many leading developments of nanoparticles and their applications throughout radiotherapy fo-
cus on localised dose enhancement and sensitisation. The basis of nanoparticle sensitisation uses
the theory that drugs containing high-Z atoms induce local electron emission and dose enhance-
ment [26]. Biston et al (2004) show that a cis-platinum chemotherapy and X-ray radiotherapy
treatment regime is an effective technique for treating radioresistant (F98) gliomas, supporting
the benefits of high-Z materials in tumour sensitisation [27]. Furthermore, Butterworth et al
(2010) utilise gold nanoparticles in the field of 160 kVp X-rays at a concentration of 100 µg/ml
to achieve a dose enhancement factor of 1.9 using human primary fibroblast cells [28].
The biocompatibility of nanoparticles and degree of tumour selectivity is the biggest issue that
is largely unresolved and requires further development [29]. The promising pre-clinical indica-
tions that have been shown throughout nanoparticle-coupled therapies highlight the importance
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of bimodal approaches in radiotherapy and how they can positively impact on patient outcomes.
2.4 Cerium oxide nanoparticles
Cerium oxide is a rare earth metal oxide that can be synthesised using numerous methods in-
cluding microemulsion, hydrothermal, flame spray and spray pyrolysis [7, 10, 29, 30]. Cerium
oxide originates with greatest abundance from the lanthanide series, making it a sustainable re-
source that can be used with a long-term perspective. The diverse range of industrial applications
that incorporate CeO2 NPs include gas sensing, cometics, sunscreens and catalysis [5, 31]. Ex-
tension into the biomedical domain has shown promising results. Cerium oxide nanoparticles
have illustrated their potential in mitigating excessive levels of oxidative stress that are prevalent
throughout conditions such as neurological disease and radiation-induced damage [5, 32]. The
unique ability to alleviate oxidative stress via an antioxidant pathway is a common approach
used in a number of studies that minimise radiation-induced toxicities and damage. The limited
success in finding an optimal compound or material that can effectively minimise effects such
as radiation-induced toxicities has resulted in the development of new and innovative materials
(including CeO2 NPs) as an alternative to existing interventions.
Despite the promising results that has been shown throughout the therapeutic application of CeO2
NPs, inconclusive evidence exists with respect to any adverse biological effects that CeO2 may
possess [7,33]. Continued research and development will elucidate the realistic potential of CeO2
NPs as a therapeutic intervention in the future.
2.5 Auto-regenerative free-radical scavenging
The proposed mechanism that CeO2 NPs use in their radiation protection application is centered
around a unique free radical scavenging ability. Biological environments with increased or ex-
cessive levels of oxidative stress, including those in the fields of ionising radiation, would benefit
from free-radical scavenging interventions. Using this approach, oxidative concentrations could
be stabilised to levels that retain and support normal and healthy cellular functions.
The free-radical scavenging mechanism of CeO2 NPs is closely linked to its superficial oxy-
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Figure 2.3 The X-ray photoelectron spectroscopy (XPS) depicts the relative intensity of photoelectrons
as the incident X-ray energy is increased. The nature of the CeO2 XPS spectra shows the presence of
cerium’s trivalent and tetravalent states, providing evidence of the autoregenerative free-radical scavenging
mechanism that CeO2 NPs inherit [10].
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gen vacancies. Clustered vacancies are proposed as the primary site that interactions such as
scavenging ROS occur [34]. The growing scientific interest has been built around the reported
autoregenerative scavenging ability of CeO2 NPs, which has the potential to mitigate the need
for periodic re-dosing.
Cerium is known to exist in two primary states: Ce3+ and Ce4+, where oscillations between these
valence states (Ce3+-Ce4+-Ce3+) provides the pathway for catalysis (i.e. the donation/acceptance
of oxygen) [5,35]. A series of oxidation and reduction reactions have been proposed by Tarnuzzer
et al (2005) and Celardo et al (2011) that outline the probable steps involved in the scavenging
and autoregeneration process [5, 10].
Tarnuzzer et al (2005) performed a X-ray photoelectron spectroscopy study to illustrate and con-
firm the presence of ceria atoms existing in both trivalent and tetravalent states (Figure 2.3). The
differences in binding energies required to emit X-ray photoelectrons is indicative of the com-
plex, dual structure of ceria atoms that exists on the surface of CeO2 NPs [10]. The increased
reactivity of Ce3+ compared to the more stable Ce4+ is the basis of the catalytic processes in-
volved with CeO2 NPs [5]. Deshpande et al (2005) find that increasing concentrations of Ce3+
(i.e. increasing the Ce3+/Ce4+ ratio) occurs with decreasing particle size. Concentrations of
Ce3+ on the surface decrease from as high as 44 % for 3 nm CeO2 NPs to 17 % for 30 nm CeO2
NPs [36]. This phenomena is supported by the fact that decreases in particle size increases the
surface area to volume ratio thus, increasing the Ce3+ concentration.
It is evident that the free-radical scavenging ability of CeO2 NPs has the potential to function
in an autoregenerative manner through oscillations between Ce3+ and Ce4+ valency states. The
distinct advantage of an autoregenerative antioxidant highlights the exciting prospects that CeO2
NPs may offer throughout radiation protection. Synthesising and developing CeO2 NPs with a
decreased particle size can be an avenue to optimise its scavenging and radioprotection efficacy
and other characteristics, including cellular internalisation.
2.6 Internalisation of NPs into cells
The development of medical applications using nanomaterials requires a comprehensive under-
standing of how the material interacts with biological systems. The main concern associated with
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the use of nanomaterials relates to the ability of nanoparticles to internalise within cells and the
subsequent effect this has on routine cellular function. Insight into both the extent and pathway
of internalisation can also be exploited to optimise therapeutic effects i.e. targeted drug delivery
to normal cells to facilitate and optimise radiation protection.
No definitive conclusions have been made in regard to the mechanisms responsible for the in-
ternalisation of CeO2 NPs. There are many detailed and complicated processes involved in
nanoparticle internalisation, some that extend beyond the scope of our study, however the essen-
tial processes are outlined throughout this section. The material and cellular characteristics that
have been suggested to influence cellular internalisation include both the cell type, and material
characteristics, including ; size, agglomeration state, zeta potential, exposure time and concen-
tration [29, 30, 38]. The reported pathways of internalisation include: cell membrane diffusion,
cell membrane binding leading to pinocytosis or phagocytosis and receptor-mediated endocyto-
sis [31, 37]. Following internalisation, the nanoparticle can be distributed to specific organelles
within the cell such as the cytoplasm, lysosomes, endoplasmic reticulum and the nucleus [39].
A recent study by Limbach et al (2005) report that the internalisation of CeO2 NPs is not signif-
Figure 2.4 The outlined mechanism demonstrates the pathways of cellular uptake of CeO2 NPs with zeta
potentials of varying polarity. Positively charged particles adsorb to the Tf protein which selectively targets
malignant cells. Furthermore, the receptor-mediated and nonspecific pathways of internalisation is shown,
suggesting an approach that can be employed for selective targeting of particles to cancer cells [37].
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icantly affected by particle concentration, however the particle size is suggested to have a strong
influence on internalisation [29]. In contrast, Busch et al (2011) report that micron-sized parti-
cles were internalised into HeLa cells and also that tungsten carbide NPs could be internalised
without any dependence on aggregation [38].
The zeta potential has also been flagged as an important characteristic that can be manipulated
to enhance internalisation [30]. This focus originates from the link between electrostatic inter-
actions and protein adsorption. Patil et al (2007) conclude that CeO2 NPs with a positive zeta
potential have an increased probability to adsorb to proteins which are commonly removed by
macrophages prior to internalisation [30]. Changes in synthesising reagents and the pH of solu-
tions is known to characterise the zeta potential, where negative potentials have been linked to
maximum cellular uptake.
An alternative approach that can be used to increase the probability of NP internalisation involves
surface modification or conjugation with compounds/materials with specific functionality. A re-
cent study by Singh et al (2010) conjugated CeO2 NPs with carboxyfluorescein to trace the
uptake and subcellular distribution of the material. The function of carboxyfluorescein reduced
aggregation which resulted in a greater internalisation efficacy [39]. Townley et al (2012) coated
CeO2 NPs with silica during synthesis and preparation to prevent aggregation and thus, maximise
particle uptake. It was also concluded that further conjugation of biological agents to the silica
surface could enable targetting to specific sites such as the nucleus [40]. A technique proposed
by Vincent et al (2009) conjugated CeO2 NPs with transferrin (Tf), a ligand protein that binds
to Tf receptors (TfRs), providing a pathway of internalisation by receptor-mediated endocytosis
(Figure 2.4) [37]. This conjugation pathway highlights a method that can be used for targetting
malignant tumour volumes that overexpress TfRs [41]. Not surprisingly, conjugating CeO2 NPs
with Tf (i.e. a protein) is most effective with positive zeta potentials, ultimately increasing the
uptake of the conjugated material within targetted sites [30].
It is clear that nanoparticle internalisation is a powerful tool that can be exploited to optimise
the therapeutic applications of nanomaterials throughout biological systems, particularly in ra-
diotherapy.
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2.7 Biocompatibility of CeO2 NPs
Many studies investigate the toxic effect of nanoparticles in an attempt to uncover the potential
hazards they can impart to biological systems. The acceptance of nanotechnology throughout the
biomedical domain has encountered many scientific concerns, particularly for human exposures.
Nanoscale particles inherit the ability to traverse cellular pathways and interact on a microscopic
scale. Understanding the subsequent health effects associated with nanoparticle exposure and
uptake is the focus of a number of studies, where outcomes have the potential to influence the
future of nanotechnology in medicine.
Developmental studies incorporating CeO2 NPs into biological systems (in-vitro & in-vivo) have
reported both inconsistent and inconclusive results, highlighting the complexity of CeO2’s func-
tion within biological environments. Xia et al (2008) report that CeO2 NPs exhibit no cytotoxic
effects to human lung epithelial (BEAS-2B) cells in-vitro, whilst resisting and protecting against
an external source induced oxidative stress [42]. In direct contrast, Park et al (2008) found that
CeO2 NPs increased the local production of ROS and induced a cascade of oxidative stress genes
to BEAS-2B cells, indicating the cytotoxic nature that CeO2 NPs may possess [43]. Colon et
al (2009) showed in-vivo biocompatibility of CeO2 NPs in athymic nude mice at relatively high
doses [7].
It is clear that conflicting data exists surrounding the toxic nature of CeO2 NPs and their poten-
tial to perturb the normal function of biological systems. The variation in toxicity reports can be
explained by changes in both nanoparticle and cellular characteristics. Characteristics that have
been suggested to influence toxic responses from CeO2 NPs include: NP synthesis, size, aggre-
gation, concentration, cellular localisation, exposure technique and exposure duration. Efforts to
elucidate a clear understanding of the factors affecting toxicity would significantly improve the
long-term outlook and use of CeO2 NPs as a novel therapeutic intervention.
2.8 Radiation protection in radiotherapy using CeO2 NPs
It has been well established that the unique free-radical scavenging characteristics that cerium
oxide nanoparticles inherit can be exploited as a means of reducing the indirect damages and
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oxidative stress arising from exposure to ionising radiation throughout biological systems. The
theoretical background of CeO2 highlights the material as an exciting potential adjuvant to ra-
diotherapy. Testing the ability of CeO2 NPs to provide radioprotection both in-vitro and in-vivo
can reveal the true potential of CeO2 as a novel radioprotector.
The potential of CeO2 NPs to function as a radioprotector has driven the direction and focus of
research groups worldwide. What is clearly established throughout the literature is the ability
of CeO2 NPs to at least confer radiation protection using both cell culture and murine mod-
els [7, 10, 32, 44]. An animal study revealed a reduction in radiation-induced dermatitis and
increases in post-treatment salivary production in the presence of CeO2 - a promising clini-
cal indication for reductions in radiation-induced head and neck toxicity [44]. Another study
highlights the radioprotective abilities of nanoceria by illustrating their role and effectiveness to
protect against radiation-induced pneumonitis, otherwise known as inflammation of the lung [7].
The absence of CeO2 resulted in visible signs of pneumonitis with histological evidence show-
ing widespread macrophage invasion. Interestingly, Tarnuzzer et al (2005) uncovered a selective
radioprotective mechanism of nanoceria (Figure 2.5). It was shown that immortalised normal
breast epithelial (CRL8798) cells showed almost complete protection from radiation-induced
apoptotic death [10]. In contrast, irradiation of breast carcinoma (MCF-7) cells in the presence
of CeO2 NPs showed no significant or measurable levels of radiation protection [10]. Similarly,
nanoceria has also shown dual functionality, acting both as a radiation sensitiser and protectant
in-vitro [33]. Wason et al (2012) reveal dose enhancement effects when irradiating pancreatic
cancer cells in the presence of CeO2 NPs. Interestingly, it was shown that normal pancreatic
cells are protected against concurrent radiation-induced damage [33].
The pre-clinical indications shown throughout the applications of CeO2 as a radiation protec-
tion “drug” highlights its potential to further increase the therpetuic index of radiation therapies
around the world. It is clear that further investigation is required, however, upon reading the
literature it is suggested that CeO2 NPs may provide radioprotection in a selective manner -
protecting normal cells whilst providing no protection or even enhancement to malignant sites.
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Figure 2.5 Comparison of cellular viability for normal (left) and cancerous (right) breast cells following
irradiation to a dose of 10 Gy in the presence and absence of CeO2 NPs, demonstrating a selectivity to
protect normal cells against radiation-induced damage [10].
2.9 Summary
Innovative studies are emerging, incorporating nanoparticles as a radiation protection adjuvant
to radiotherapy. The current literature provides a comprehensive overview and outline of novel
nanoparticle coupled therapies with applications ranging from diagnostic imaging, radiation en-
hancement to radiation protection. Cerium oxide nanoparticles have demonstrated their potential
to provide radiation protection through a unique free-radical scavenging ability. Reductions in
radiation-induced oxidative stress is the suggested pathway and mechanism used by CeO2 NPs,
masking part of the indirect damages that occur during radiation exposures. Knowledge and in-
formation presented throughout this review is an essential contribution that is used to guide and
inform research directions and objectives. An understanding of the biological toxicity of CeO2
NPs is required to ensure techniques can be implemented to mitigate harmful effects and retain
biological functionality. The efficacy of CeO2 NPs to provide radiation protection to normal and
cancerous cell is a noted gap that exists throughout current literature. The TNT team and collab-
orators have a focus to provide novel contributions to the use of CeO2 NPs as a radioprotector,
with a primary focus to elucidate and demonstrate any changes in efficacy when irradiating cells
using different beam qualities (i.e. kV and MV X-ray beams).
The aforementioned research objectives will undoubtedly provide positive contributions to the
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development of CeO2 NPs as a radioprotector. In the near future, CeO2 NPs could be used as a
clinical intervention, enhancing radiotherapy practices around the world.
Chapter 3
Materials and Methodology
3.1 Cell lines
Two cell lines (9L and MDCK) were utilised as test subjects throughout all experimental work. A
rat brain gliosarcoma cell line (9L) was obtained from the European Collection of Cell Cultures
(ECACC). Derived from a N-nitrosomethylurea-induced tumour, the adherent and radioresistant
cell line inherits glial morphology. A canine kidney cell line (MDCK - Madin Darby Canine
Kidney), purchased from Sigma-Aldrich R© is an adherent, non-malignant cell line with epithe-
lial morphology. Both 9L and MDCK cell lines have undergone routine mycoplasma testing for
sterility. The cell lines used throughout this study have a level 2 biosfaety requirement. Subse-
quently, all cells and biological materials were handled within a class 2 Biological Safety Cabi-
net inside the PC2 laboratories provided at the Illawarra Health and Medical Research Institute
(UoW, NSW, Australia).
3.2 Cell culture
The 9L and MDCK cell lines were both grown and cultured during their exponential growth
phase in T75 cm2 BD FalconTM tissue culture flasks (Franklin Lakes, NJ, USA) containing
Dulbecco’s Modified Eagle Medium (DMEM) with L-Glutamine, supplemented with 10 % (v/v)
Fetal Bovine Serium (FBS) and 1 % (v/v) Penicillin/Streptomycin (PenStrep). Cell cultures were
passaged upon reaching 85 % confluence to a concentration of 2 - 4 × 104 cells/cm2 for 9L cells
and 1 - 3 × 104 cells/cm2 for MDCK cells. The cell cultures were grown under ideal growing
conditions inside a cell culture incubator operating at 37◦C amd 5 % CO2. Experimental work
deduced the cell doubling time to be 36 h and 20 h for 9L and MDCK, respectively. All chemical
reagents were purchased from GIBCO R©, unless indicated otherwise. A comprehensive list of
chemical reagents used is presented in Appendix A.
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3.3 Nanoparticle synthesis and preparation
The cerium oxide nanoparticle sample was produced at the Institute for Superconducting and
Electronic Materials (Wollongong, NSW, Australia) using a spray pyrolysis technique [45, 46].
The spray pyrolysis technique was utilised due to the high purity and chemical homogeneity that
can be achieved, producing a nanoparticle sample with highly reproducible characteristics. A 1 L
aqueous solution was prepared, consisting of 0.45 mol/L of Ce(NO3)3 and 6H2O. This solution
was sprayed and decomposed at 500◦C using a customised spray pyrolysis system designed for
the engineering of nanoceramics and composites. To minimise moisture absorption, the cerium
oxide NP samples were dried inside an Aluminium crucible in an open furnace operating at
140◦C for a period no less than 2 h prior to sterilisation. Sterilisation of the CeO2 NP sample was
performed to maximise biocompatability. To achieve sterility, an autoclave operating at 121◦C on
a dry cycle was utilised, with the sterilised samples kept in glass vials surrounded by silica gel to
avoid moisture absorption. CeO2 NPs were dispersed in Dulbecco’s Phosphate Buffered Saline
(DPBS) to solubilise the NP in preparation for cellular exposure. Sonication and subsequent
vortex mixing was used to minimise the aggregation of the NP, increasing the homogeneity of
the NP dispersion.
3.4 X-ray Diffraction
X-ray diffraction analysis was performed to extract properties of the CeO2 NP sample including -
phase composition, NP crystallite size and basic crystalline structure. A slurry of the nanoparticle
was prepared by vigorously mixing the CeO2 powder with 100 % ethanol which was then placed
onto a quartz sample holder. The sample was presented to a monochromatic, Cu Kα X-ray
beam (λ = 1.5406 Å). The X-ray diffraction analysis was performed using an automated GBC R©
eMMA X-ray Diffractomoeter (GBC, Vic, Australia) where the sample was analysed using a
step size of 0.2◦ 2θ through the range of 20◦ - 70◦ 2θ with a count time of 8.75 seconds per step.
The operational settings used were 25 mA and 40 kVp. The structure and phase identification
was deduced through a comparison of the recorded diffraction pattern and the Inorganic Crystal
Structure Database (ICSD). The average nanoparticle crystallite size (Tc) is extracted from the
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Figure 3.1 Example of the X-ray diffraction apparatus used to perform the diffraction analysis of our
CeO2 NP sample.
X-ray diffraction data using Scherrer’s formulation 3.1.
Tc =
Kλ
βcos(θB)
(3.1)
K is the shape factor constant (K = 0.89), λ is the X-ray beam wavelength, β is the FWHM (in
radians) and θB is the Bragg angle.
3.5 Microscopic analysis
Scanning and transmission electron microscopy techniques were utilised to primarily observe
the morphology of the NP sample. Other characteristics such as crystallite size and structural
features were observed and used to compliment alternative analysis such as X-ray diffraction.
3.5.1 Scanning Electron Microscopy
Scanning electron microscopy (SEM) was performed using a JEOL JSM-6460A analytical scan-
ning electron microscope, characterising the effect of sonication on the size and abundance of
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Figure 3.2 Example of the scanning electron microscopy (SEM) apparatus used to investigate the effect
that sonication has on the aggregation of nanoparticle samples.
NP aggregates under the experimental dispersion in DPBS.
3.5.2 Transmission Electron Microscopy
Transmission electron microscopy (TEM) was performed using a JEOL 2011 high resolution
(HR) instrument, characterising the size and morphology of the sample. The samples were pre-
pared by dispersion of CeO2 powders onto holey carbon support films.
3.6 Gas sorption analysis
The surface area to volume ratio is particularly large for nano-sized particles and follows an in-
verse proportionality with radius. To quantify the specific surface area of the CeO2 NP powdered
sample, the Brunauer-Emmett-Teller (BET) method was used with a Nova 1000 high speed gas
sorption analyser from Quantachrome, using the adsorption of N2 at the temperature of liquid
nitrogen. Prior to measuring, the samples were degassed at 120◦C for 2 h 30 min in vacuum.
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3.7 Flow cytometry
After exposure to CeO2 NPs for 24 h, 9L cells were detached using trypsinisation and sub-
sequently centrifuged at 1500 rpm for 5 min at 4◦ C prior to rinsing twice with cold PBS
(without Ca2+ & Mg2+). Flow cytometric measurements and analysis were performed using
a Becton-Dickinson fluoresence-activated cell sorting (FACS) flow cytometer (BD LSR II; BD
Biosciences, Franklin Lakes, USA). Each analysed sample contained a minimum of 10,000 cells
where cell doublets and aggregates were gated out using a two parameter histogram of FL2-Area
versus FL2-Height. Data analysis was performed using the FACSDiva software, assessing both
forward and side scatter intensities. The median cell side scatter (SSC) values were utilised as
the marker for cellular granularity which is proportional to particle uptake and internalisation.
3.8 Clonogenic cell survival assay
The clonogenic cell survival assay, otherwise known as the colony-forming assay was the tech-
nique used to assess cell survival and viability. The clonogenic assay was used for both an
assessment of the toxicity of CeO2 NPs upon exposure to cell cultures at a range of concentra-
tions, and also to investigate the cell survival following radiation exposure at different doses.
Adherent cell lines have the ability to form colonies in-vitro at low density seeding over a typi-
cal incubation period of 15 doubling times. The main advantage associated with the clonogenic
assay technique is the ability to distinguish between both cytostatic (i.e. decreased growth rate)
and cytotoxic (i.e. non-viable) effects. To initiate the clonogenic assay, the growth medium was
removed and the confluent cell culture thoroughly washed using DPBS (without Ca or Mg salts).
The cells are then detached from the surface of the flask with a 2 minute (9L) or 10 minute
(MDCK) incubation with 0.05 % trypsin ethylenediaminetetraactic acid (Trypsin-EDTA), form-
ing a cell suspension that is counted using a haemocytometer. Cells are seeded at low densities
in triplicate into 100 mm Sigma-Aldrich R© (9L) or 100 mm BD FalconTM (MDCK) petri dishes
containing 10 ml of DMEM and incubated at 37◦C and 5 % CO2 for 15 cell doubling times.
Each experimental condition (i.e. dose and/or concentration) utilised a maximum of three dif-
ferent cell seeding numbers, all determined by preliminary experiments to narrow the optimal
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Figure 3.3 Example of a stained plate showing the presence of 9L cells which have formed colonies during
the clonogenic assay procedure.
seeding to achieve approximately 100 colonies. At the conclusion of the incubation period, the
colonies that have formed were fixed and stained using a mixture of 70 % (v/v) ethanol and 25 %
(v/v) crystal violet. Colonies containing 50 cells or more (confirmed using a high powered in-
verted microscope) are scored for analysis as they’re considered viable, retaining the ability to
indefinitely proliferate.
The clonogenic cell survival data is typically presented with a plot of the surviving fraction of
cells as a function of absorbed dose or concentration of the NP. The surviving fraction is deduced
through a ratio of plating efficiencies at a given condition (i.e. x Gy) to a reference condition
(i.e. a control). The plating efficiency (PE) is calculated as the number of scored colonies to cells
seeded.
PE =
No. of scored colonies
No. of cells seeded
(3.2)
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3.9 Statistical analysis
The cell survival experimental analysis reports values that are measured in triplicate (as a min-
imum) with replication performed in most cases. The reported values are the mean from all
experimental data with an uncertainty given as one standard deviation. All irradiation cell sur-
vival data sets were fitted with the linear quadratic (LQ) model using a script compiled with
KaleidaGraph. The fit to the data is weighted by the magnitude of the error at each data point.
Statistical analysis of the toxicity data was performed using a two-tailed Student’s t-test using
the assumption of equal variance. A P value of ≤ 0.05 was considered statistically significant.
3.10 Cell survival analysis
Using the compiled cell survival data set from an irradiation experiment, a cell survival curve
can be constructed on a semi-logarithmic plot of the surviving fraction as a function of absorbed
dose. The cell survival data can be modelled mathematically using the LQ model. The LQ model
adequately predicts the cellular response to radiation, particularly for low-LET radiations such
as X-rays [2, 12, 15, 23, 24].
SF (D) = exp(−αD − βD2) (3.3)
The constants α (Gy−1) and β (Gy−2) are indicators of cellular radiosensitivity and the repair
capacity of cells, respectively.
Upon fitting the surviving fraction data to the LQ model, the radiobiological parameters (α & β)
were extracted for each set of cell survival data.
3.11 Protection enhancement ratio
The Protection Enhancement Ratio (PER) is a value that is used to quantify and measure the
degree of protection (if any) achieved using CeO2 NPs. The PER can be defined as the ratio of
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doses in the presence of CeO2 to the control (i.e. no NP), measured at the common endpoint of
10 % cell survival.
PER =
DoseCeO2
Dosecontrol
(3.4)
A PER value greater than 1 is indicative of radioprotection, where in contrary, a PER value less
than 1 reveals an enhancement and sensitisation effect. By definition, any effect is manifested as
a direct result of the presence of CeO2 NPs.
3.12 Cellular irradiation
All irradiations were performed in the radiation oncology department at the Prince of Wales
Hospital (Randwick, NSW, Australia). In all cases, the confluent cell culture was irradiated
following a 24 h exposure period with CeO2 NPs at a concentration of 50 µg/ml. Prior to mega-
voltage irradiation, non-vented T12.5 cm2 tissue culture flasks were filled with Hank’s Balanced
Salt Solution (HBSS), ensuring no air bubbles were present inside the flask and importantly, in
the path of the beam - maximising the accuracy of the dose delivered at the depth of the cells.
In contrast, kilovoltage irradiation was performed using only a 6 mm depth of medium in an
attempt to maximise the accuracy of the dose delivered to the cell monolayer. Beam energies
of 10 MV and 150 kVp were utilised and delivered from an Elekta AxesseTM LINAC (Elekta
AB, Kungstensgatan, Stockholm, Sweden) and a Nucletron Oldelft Therapax DXT 300 Series 3
Orthovoltage unit (Nucletron B.V., Veenendaal, The Netherlands), respectively. All doses were
delivered in single fractions at room temperature, ranging from 1 - 8 Gy. As shown in figure
3.4, the tissue culture flasks containing the cells were irradiated in a horizontal orientation with
solid water placed both underneath and surrounding the sides of the flasks to provide adequate
backscattering and to stabilise electronic equilibrium. Unirradiated control samples (i.e. with
and without NP) were utilised and handled under the same conditions as the irradiated samples.
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Figure 3.4 Schematic of the setup used to irradiate the cultured cells in flasks for MV and kV irradiations at
POWH. The flasks are surrounded with water equivalent back and side scatter to maximise the accuracy of
dose delivery, maintaining adequate electronic equilibrium and to construct a reproducible and consistent
setup for future experimentation.
Chapter 4
Results
4.1 Characterisation of cerium oxide nanoparticles
A thorough understanding of the various structural and physical characteristics (including phase
composition) is an essential step towards the effective utilisation of such a material. It has been
well established that the biochemical effects of nanoparticles are determined from their structural
and physical characteristics. In biological applications, characterisics of interest can include:
phase composition, crystalline size, structure and specific surface area.
4.1.1 X-ray diffraction
X-ray diffraction (XRD) was the primary characterisation technique used due to the vast and
quality of information that it can reveal. The first order diffraction peaks in the resultant XRD
spectra (Figure 4.1) have been labelled with Miller indices following correlation with the ICS
database (PDF card no. 01-089-8436). Subsequently, the phase of the NP sample is confirmed
to exist as CeO2 and not its unstable counterpart, Ce2O3. The CeO2 NP phase is consistent with
the phase of nanoceria that has been reported to provide protection against radiation-induced
damage [7, 10, 44, 47]. Analysis of the XRD data confirms the nanocrystallinity of the sample,
with a simple cubic crystal structure (a = 5.4112 Å). Furthermore, the mean crystallite size can be
deduced from the XRD peaks using Scherrer’s equation (equation 3.1). To maximise accuracy,
analysis is performed only on pronounced peaks that are free of contribution from any satellite
peaks. The crystallite size was calculated to lie within the range of 6 - 8 nm.
4.1.2 Electron microscopy
Electron microscopy techniques were performed to primarily investigate the NPs morphology
and size. Both scanning (SEM) and transmission (TEM) modalities were employed due to both
physical limitations and availability of equipment and the respective qualified professionals.
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Figure 4.1 X-ray diffraction spectra of CeO2 NPs synthesised by a spray pyrolysis technique. The Miller
indicies that index each peak show excellent agreement to the data published in the Inorganic Crystal
Structure Database. The operational settings used were 25 mA and 40 kVp, measuring through the range
of 20◦ - 70◦ 2θ.
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Figure 4.2 Scanning electron micrograph of CeO2 NPs, illustrating the morphology of the material before
(A) and after (B) sonication, confirming the proper functioning of the sonication process. Sonication was
performed using 10 minute runs repeated 3 times for consistency and reproducibility purposes.
4.1.2.1 Scanning Electron Microscopy
Ceramic nanoparticles such as CeO2 exhibit a strong predisposition to form aggregates in their
dispersions. The extent of aggregation is observed to increase with NP concentration, with sever-
ity depending on the composition of the solution used for dispersion.
Sonication was an approach used to minimise implications that may arise from the presence of
NP aggregates by reducing their size and thus, improving the homogeneity of the dispersion. A
qualitative analysis was performed using SEM to observe the effect of sonication on the size of
CeO2 NP aggregates when dispersed in DPBS. Figure 4.2 depicts the effect of sonication on the
size of nanoparticle aggregates. It can be seen that their size has on average, been reduced, with
the overall homogeneity of the sample being increased.
4.1.2.2 Transmission Electron Microscopy
Transmission electron microscopy was performed as a supplement to the X-ray diffraction anal-
yses. A focus was placed on investigating the morphology of the NP with an attempt to discern
any properties of the crystal structure. The HR-TEM image (Figure 4.3) consolidates the crys-
tallite size range reported (6 - 8 nm), where the presence of lattice fringes is clear and distinct.
Upon further analysis, the average fringe spacing (d) was calculated to be 3.15 Å, corresponding
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Figure 4.3 High resolution transmission electron microscopy image showing the structure and size of our
CeO2 sample. The presence of lattice fringes is used to confirm structural characteristics and deduce the
lattice parameter. Results show excellent agreement with the ICSD.
to the distance between the 1 1 1 lattice planes of CeO2 (a = 5.4112 Å).
d =
a√
h2 + k2 + l2
(4.1)
Where d is the fringe spacing, a is the lattice parameter and h, k and l are the Miller indices
associated with the cubic structure of the material.
4.1.3 Surface area analysis
The specific surface area of CeO2 NPs was calculated using the BET method to be 51 m2/g,
supporting the notion that NPs in general have large available surface areas, increasing the prob-
ability for chemical reactions and other various processes to occur.
4.2 Toxicity investigations
No conclusive data exists throughout the literature in regard to the toxicity of CeO2 NPs [7, 10,
44, 48]. Many studies perform investigations in an effort to determine the biological viability of
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Figure 4.4 The surviving fraction of 9L cells measured using the clonogenic cell survival assay. The
toxicity was determined following exposure of 9L cells to CeO2 NPs at increasing concentrations up to
500 µg/ml. Uncertainties are presented with one standard deviation and statistical significance measured
with a P value ≤ 0.05.
CeO2 NPs [34, 35, 42, 43, 48–50].
In an attempt to contribute to the cohort of data and increase the overall understanding of the
toxic nature of CeO2 NPs, toxicity investigations on 9L and MDCK cells were performed. The
clonogenic cell survival assay was performed following a 24 h incubation period at a range of
concentrations up to 500 µg/ml. The optimum incubation period (i.e. 24 h) was deduced in
preliminary developmental work as a suitable and convenient exposure period that has negligible
toxicity yet long enough to enable cellular uptake. Conflicting degrees of toxicity from CeO2
NPs between 9L and MDCK cells is observed, with most significance observed at higher con-
centrations. However at concentrations up to 50 µg/ml, similar trends in toxicity was observed
(Figures 4.4 & 4.5). At 50 µg/ml, surviving fractions of 0.93 ± 0.07 (9L; P value: 0.2, CeO2 vs
no NP control) and 0.99 ± 0.07 (MDCK; P value: 0.9, CeO2 vs no NP control) were recorded.
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Figure 4.5 The surviving fraction of MDCK cells measured using the clonogenic cell survival assay. The
toxicity was determined following exposure of MDCK cells to CeO2 NPs at increasing concentrations up
to 500 µg/ml. Uncertainties are presented with one standard deviation and statistical significance measured
with a P value ≤ 0.05.
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Figure 4.6 The light micrograph shown was taken to investigate the anatomical position of CeO2 NPs.
Inconclusive results are shown here, however a random distribution is observed with the NP location
surrounding or lying within 9L cells.
4.3 Anatomical position of CeO2 NPs in the cellular environ-
ment
The anatomical location of CeO2 NPs following exposure to cellular environments in-vitro is
an important characteristic which should be well understood. Light micrographs of 9L cells
incubated with CeO2 NPs over a 24 h period illustrate a random distribution - surrounding,
bound or internalised inside the cells. Light microscopy is insufficient to observe intracellular
localisation and flow cytometric analysis was performed as a supplement analysis. Following the
incubation of 9L cells with CeO2 NPs, increases in cell side scatter occurs indicating an increased
granularity of the cellular contents. The flow cytometric analysis thus provides some evidence
of cellular internalisation of CeO2 NPs inside 9L cells (Figure 4.7).
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Figure 4.7 The flow cytometric analysis shows the relationship between the forward and side directed
cell scatter. Increases in the cell side scatter is an indirect measure of the nanoparticle internalisation. It
is shown that the CeO2 increases the measured cell side scatter and thus, their internalisation within 9L
cells.
4.4 Cellular irradiation
4.4.1 Development of cell handling requirements for irradiation proce-
dures
Preliminary studies were conducted to establish and optimise the cellular irradiation experiments
using CeO2 NPs. Understanding the cellular characteristics and response to X-rays in the pres-
ence and absence of CeO2 NPs for each cell line built the complex matrix of preliminary work
that was undertaken. The response of the cell lines (9L and MDCK) vary from each other for a
given dose of radiation. The plating efficiencies (PE) are required with a level of accuracy such
that an appropriate number of colonies can be counted using the clonogenic cell survival assay,
providing the surviving fractions (SF) required to construct cell survival curves. A ’trial and er-
ror’ approach was used to uncover the appropriate plating efficiencies for the range of conditions
outlined above. Knowledge and experience gained from these studies will prove invaluable to
future work within the TNT team when using 9L and MDCK cells under X-ray radiation fields
in the presence and absence of CeO2 NPs. An example of the optimisation can be explained
where initial plating cell numbers of 2,400 cells for 9L cells at a dose of 1 Gy in the presence of
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CeO2 NPs has been refined to 2,000 cells. Further experience has shown that for absorbed doses
in the range from 1 - 8 Gy, that identical plating numbers may be used for both kilovoltage and
megavoltage X-ray beams.
4.4.2 X-ray beam energies for cellular exposure
Two different X-ray beams were used for all cellular irradiation investigations. A low energy
150 kVp X-ray beam and a 10 MV photon beam were used primarily for their large differences
in beam quality. The 10 MV photon beam was chosen arbitrarily as this was the highest avail-
able X-ray energy for use at the Prince of Wales Hospital. The 150 kVp beam was chosen in
an attempt to maximise the dose enhancement imparted to the CeO2 doped medium to a water
equivalent medium, based on the method described by Corde et al. The effective energy required
to produce maximum dose enhancement can be calculated using the following relationship:
DCeO2 = DH2O ×
(µen
ρ
)CeO2
(µen
ρ
)H2O
(4.2)
where DCeO2 and DH2O is the dose delivered to the CeO2 doped medium and the water equiva-
lent medium, respectively. The mass-energy absorption coefficients (µen
ρ
)x for each medium x is
obtained from data published by the National Institute of Standards and Technology (NIST).
Using the formalism outlined in equation 4.2, the effective energy that has the potential to pro-
duce maximum dose enhancement is 54 keV (Figure 4.8).
To determine the X-ray beam quality that satisfies the requirement of targeting maximum dose
enhancement, spectra of the available superficial and orthovoltage X-ray beams were generated
using the SpekCalc X-ray spectrum generator. It was concluded that the 150 kVp X-ray beam
(Figure 4.9) satisfied the criteria and was subsequently used throughout the following cellular
irradiation experiments.
4.4.3 9L cells
The 9L cells were irradiated at a range of doses up to 8 Gy in the presence and absence of CeO2
NPs at a concentration of 50 µg/ml. Both, 150 kVp and 10 MV beams were used to investigate
any changes in radioprotection efficacy that may be experienced using different beam energies.
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Figure 4.8 The relationship between the ratio of the mass-energy absorption coefficients (CeO2:H2O)
and energy is used to indicate the effective energy that results in maxmimum dose enhancement. The
relationship shows that the effective energy required to maximise the dose enhancement from a NP doped
medium is 54 keV.
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Figure 4.9 The X-ray spectra shown demonstrates the relative X-ray emission intensities as a function of
energy. The spectra of the 150 kVp orthovoltage X-rays are generated using SpekCalc, a X-ray spectrum
generator [51].
The data presented throughout figures 4.10 & 4.11 is a compilation of two independent experi-
ments, where each data point consists of a minimum of three individual points and a maximum
of nine, consolidating the precision that can be obtained with the clonogenic cell survival assay.
The results of this investigation show that the efficacy of CeO2 NPs to provide protection from
radiation-induced damage varies with the treatment beam energy (Figures 4.10 & 4.11). Clear
and distinct radiation protection is achieved relative to control samples in the field of 10 MV
photons at all doses measured (Figure 4.10). Further characteristics such as changes in radiosen-
sitivity and the ability of cells to repair can be extracted from the radiobiological parameters -
α & β. Analysis indicates that the presence of CeO2 NPs results in a decrease in the radiosen-
sitivity with a corresponding increase in damage repair (Table 4.1). A protection enhancement
ratio (PER) of 1.230 ± 0.003 is achieved from the 10 MV treatment, consolidating the notion
that CeO2 NPs provide radiation protection. In contrast, an inverse effect is shown from 150 kVp
irradiations where similar cell survival curves are produced in the presence and absence of CeO2
NPs (Figure 4.11). The influence of the high-Z component of CeO2 is illustrated through the
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Figure 4.10 Clonogenic cell survival curve of 9L cells following 10 MV irradiation in the presence and
absence of CeO2 NPs at a concentration of 50 µg/ml. All uncertainties are presented using one standard
deviation.
change in efficacy with beam energy. Subsequent analysis reveals a minor increase in radiosensi-
tivity of 9L cells exposed to CeO2 NPs (Table 4.1). The linearity of the survival curves suggests
an increase in the RBE of radiations which may be influenced by the high-Z component CeO2.
The similarity of the survival curves in the presence and absence of CeO2 is supported by the
PER value lying close to unity. The variation in PER with treatment beam energy supports the
hypothesis that CeO2 NPs possess an energy-dependent radioprotection efficacy.
4.4.4 MDCK cells
Non-malignant MDCK have been included in a pilot study to not only investigate the efficacy of
CeO2 NPs to provide radioprotection, but to further develop the technique of performing in-vitro
radiations and the clonogenic cell survival assay on the MDCK cell line.
Similarly to 9L, the MDCK cell line was exposed to CeO2 NPs at a concentration of 50 µg/ml
during a 24 h incubation period prior to irradiation. The cells were exposed using the 150 kVp
and 10 MV X-ray beam qualities at a range of dose up to 5 Gy. The reduction in dose comes at a
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Figure 4.11 Clonogenic cell survival curve of 9L cells following 150 kVp irradiation in the presence and
absence of CeO2 NPs at a concentration of 50 µg/ml. All uncertainties are presented using one standard
deviation.
Table 4.1
Summarised radiobiological constants for 9L cells exposed to 10 MV and 150 kVp X-rays in the presence
and absence of CeO2 NPs. The LQ model was used to fit the surviving fraction data in KaleidaGraph,
extracting the α and β constants. All uncertainties listed are given as one standard deviation.
Experimental parameters
Control 50 µg/ml
Radiation source α (Gy−1) β (Gy−2) α (Gy−1) β (Gy−2)
150 kVp X-rays 0.21 ± 0.03 0.009 ± 0.004 0.30 ± 0.04 0.000 ± 0.007
10 MV photons 0.20 ± 0.06 0.013 ± 0.008 0.06 ± 0.04 0.019 ± 0.005
consequence of the increase in sensitivity of non-malignant cells to radiation. The results reveal
cell survival curves with similar trends as a function of treatment beam energy (i.e. 150 kVp and
10 MV) as observed using 9L cells. A trend of radioprotection is observed at megavoltage en-
ergy and enhancement at kilovoltage energy in the presence of CeO2 NPs (Figure 4.12 & 4.13).
The change in efficacy can account for the subtle variations observed. The change in efficacy is
believed to be driven by excitation of the high-Z cerium atoms present in the NPs structure. The
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Figure 4.12 Clonogenic cell survival curve of MDCK cells following 10 MV irradiation in the presence
and absence of CeO2 NPs at a concentration of 50 µg/ml. All uncertainties are presented using one
standard deviation.
preliminary experiments show that the non-malignant MDCK cells are far more radiosensitive
than the radioresistant 9L cells however, we are still observing indications of the changing radio-
protective efficacy with changes in the treatment beam quality. The radiobiological parameters
are not extracted from the MDCK cell survival curves presented as the method used to extract
these parameters will not accurately depict the true relationship due to the inadequate data at the
1 Gy dose.
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Figure 4.13 Clonogenic cell survival curve of MDCK cells following 150 kVp irradiation in the presence
and absence of CeO2 NPs at a concentration of 50 µg/ml. All uncertainties are presented using one
standard deviation.
Chapter 5
Discussion
Many current and innovative studies focus on investigating the application and functionality of
CeO2 NPs throughout radiation protection. Nanoscale medicine is a rapidly evolving approach
to traditional techniques, including - diagnostic imaging, radiotherapy and radiation protection.
The stimulus for the number of new and novel approaches to radiation protection is driven by
the desire to minimise radiation-induced side effects. An interesting approach that can be used
to provide radioprotection is the use of free-radical scavengers. The development of new and
improved radioprotectors in place of currently used radio-protective drugs such as amifostine is
essential to the future radiation protection market.
The CeO2 NPs implemented throughout the studies in this thesis have been synthesised using a
spray pyrolysis technique. It has been suggested that spray pyrolysis can be the superior pro-
duction technique due to the high yield that can be achieved along with the reproducibility of
nanoparticle characteristics including phase, size and structure [52]. Due to the variability of
characteristics depending on the method of synthesis, each nanoparticle study should include a
characterisation procedure to establish the phase and structural characteristics of their synthe-
sised material. The XRD characterisation of the CeO2 NP sample revealed details of the phase,
structure and size of the material. The nanoparticle sample exists with a single cubic phase i.e.
CeO2, as confirmed upon reference to the ICSD. The broad diffraction peaks, as shown in fig-
ure 4.1, are indicative of nano-scale materials. Using Scherrer’s formulation and analysis, the
mean crystallite size is calculated to range from 6 - 8 nm. Tarnuzzer et al (2005) have pub-
lished their XRD analysis on CeO2 NPs, who report parallel findings to results presented in this
thesis. Subsequently, it can be extrapolated to suggest that the CeO2 NP sample can exhibit sim-
ilar auto-regenerative free-radical scavenging effects and thus, provide radiation protection [10].
The presence of distinct lattice fringes in the HR-TEM image (Figure 4.3) consolidates the cubic
structure of CeO2 NPs. The fringe spacing (d) in the [1 1 1] lattice plane (d = 3.15 Å) shows
excellent agreement lattice parameter, a, as reported throughout the ICSD (PDF card no. 01-089-
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8436). The specific surface area of the synthesised nanoparticle sample was measured using a
gas sorption analytical technique. Upon analysis it was shown that the sample had a surface area
of 51 m2/g, consistent with nanoscale materials. A common property of nanoscale materials is
the relatively large surface area to volume ratio (Figure 2.2). Subsequently, it is believed that the
large surface area of the NP sample can act to maximise the free-radical scavenging properties
of CeO2.
Inconclusive and conflicting data has resulted in significant ambiguity surrounding the toxicity
of CeO2 NPs, particularly throughout their application in biological systems [43]. The toxicity
of CeO2 NPs was investigated using both 9L and MDCK cells, measuring its clonogenic survival
at a range of concentrations up to 500 µg/ml. The toxicity was measured using the same tech-
nique as applied in the radiation studies in an attempt to maximise the applicability of the result
to the subsequent irradiation procedures. Following 24 h exposures of CeO2 NPs to both 9L and
MDCK cells, insignificant toxic effects were recorded at a concentration of 50 µg/ml, consistent
with other published literature [7,10,42]. Further investigations lead to testing the toxic nature of
CeO2 NPs at higher concentrations as the influence of any oxidative stress would become more
pronounced at higher concentrations. A concentration-dependent toxicity is uncovered where
the levels of toxicity increase with increasing concentration. The surviving fraction of MDCK
cells at higher concentrations is consistently lower relative to the 9L concentration cell survival
response (Figures 4.4 & 4.5). There are many influential factors that contribute to the toxic nature
including: method of synthesis (i.e. structure and size), exposure time, concentration, cell type
and the balance of cerium’s valence states [7, 43, 49].
A distinct advantage that nanoparticles offer in general, due to their size, is the ability to travel
along cellular pathways and potentially internalise within cellular environments. Mechanisms
of action and other functional properties can be better understood through knowledge of the in-
ternalisation of CeO2 NPs. Subsequent light microscopy investigations showed that CeO2 NPs
have a random distribution around 9L cells. Flow cytometry, a technique used to measure cel-
lular granularity and internalisation has been used by Busch et al (2011). Increases in the cell
side scatter was used as a measure of nanoparticle internalisation [38]. Increases in the cell side
scatter was recorded (Figure 4.7), providing evidence that some portion of the CeO2 NPs become
internalised inside 9L cells. Future studies will investigate the ability of CeO2 NPs to be inter-
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nalised into MDCK cells using flow cytometric analysis. Advances in cellular internalisation and
specificity of nanoparticle uptake may be an avenue of research that could further advance the
knowledge of CeO2 NPs and their role in biological systems. Important implications and con-
clusions can be drawn with knowledge of the anatomical location of nanoparticles, particularly
in regard to physical processes that occur i.e. secondary electron production and their range in
close proximity to critical targets such as the nucleus of cells.
The ability of CeO2 NPs to provide protection against radiation-induced toxicities is provided
through its unique free-radical scavenging ability. These scavenging effects counteract the addi-
tional reactive oxygen species (ROS) that are present within the irradiated cellular environments.
Many studies using both cell culture and murine models have shown positive indications of
CeO2’s ability to provide radioprotection however much more development is required prior to
utilisation in clinical trials. Developments required prior to clinical acceptance include how the
efficacy of CeO2 NPs is influenced by changes in: cellular radiosensitivity, NP concentration,
irradiation sources (i.e. protons, X-rays etc), the degree of internalisation and NP synthesis.
The focus of the evolving multidisciplinary research collaboration (otherwise known as the tar-
geted nano-therapies (TNT) team) has been the development of biological applications of nano-
composite materials such as CeO2. Initial work under the TNT collaboration with CeO2 NPs has
investigated the influence of the high-Z cerium atoms on the radioprotection efficacy following
changes in radiation beam quality.
Results show that CeO2 NPs provide clear and distinct radioprotection to 9L cells using 10 MV
X-rays with a deduced PER of 1.230 ± 0.003 (Figure 4.10).
The cell survival response is used more than a qualitative tool of the response of cell cultures to
increasing doses of radiation. Quantitative analysis using the LQ model provides essential ra-
diobiological information including: cellular radiosensitivity (α) and the ability of cells to repair
against radiation-induced damage (β). The presence of CeO2 NPs in the field of 10 MV X-
rays results in a decrease in radiosensitivity with a corresponding increase in the capacity of the
cells to repair, consistent with the radioprotection that is observed. It is noted that experimental
uncertainty may exacerbate or mitigate differences in the cell survival response in the presence
and absence of CeO2 NPs, however repetition of experimental work provides confidence in the
presented results. Conclusions and subsequent interpretation of experimental results have been
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offered. The uncertainties in the β-values recorded appear large, however the influence to the
survival curve is insignificant for doses ≤ 5 Gy, the point where the quadratic component of the
LQ model provides the dominating contribution.
An inverse effect is observed in the field of 150 kVp X-rays, where the presence of CeO2 NPs
results in marginal radiation enhancement, supported by a PER value that is close to unity (Fig-
ure 4.11). Further analysis of the radiobiological parameters contained within the LQ model
shows that the radiosensitivity is increased in the presence of the NP which is correlated by the
increased linearity of the survival curve. The increased linearisation of the cell survival curve is
interpreted as a change in the radiation spectrum, suggesting an increased proportion of direct
damage effects which are stimulated by clustered distributions of low energy electrons.
Despite the insignificant difference and similarities of the survival curves in both the presence
and absence of the NP, a change in efficacy is evident across different beam qualities. A recent
study by Wason et al (2012) revealed that CeO2 NPs functioned as a radiation sensitiser to pan-
creatic cancer cells using a low energy (160 kVp) X-ray source, supporting the phenomena we
observe at low energies [33].
The research direction with CeO2 NPs under the TNT team is driven by the notion that addi-
tional low energy secondary electrons may result as a consequence of the high-Z atoms con-
tained within the structure of CeO2. The reasoning behind the hypothesis is centered around
the strong Z dependence of the photoelectric effect. The mechanisms that can contribute to this
energy-dependent protection efficacy can be explained as a counterbalance between the known
free-radical scavenging ability and the increase in RBE induced from lower energy radiations.
It is thought that the increase in RBE is influenced by the targeted dose enhancement through
exploitation of the mass-energy absorption of CeO2 and also the high-LET Auger electrons that
are produced as an alternative to the more prevalent X-ray fluorescence (otherwise known as
characteristic X-rays). The presence of Auger electrons act to increase the average LET of the
secondary particle products, creating more clustered ionisations and thus, more direct damage.
Subsequently, in the field of 150 kVp X-rays, a greater yield of high-LET particles are produced
(i.e. a product of the photoelectric effect) in comparison to the field of 10 MV photons, support-
ing the energy-dependence that we observe (Figure 5.1).
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Figure 5.1 The energy dependence of the mass-energy absorption coefficients is illustrated for the three
main interactions of ionising radiation with matter. It is evident that at lower energies, the photoelectric
contribution dominates.
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Figure 5.2 The total mass-energy absorption coefficient as a function of energy is shown, comparing the
differences between amifostine (Z = 11) and CeO2 (Z = 54). The logarithmic scale softens the apparent
difference, however significant variations are shown.
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A pilot study was performed to observe and compare any changes in the radioprotective efficacy
of CeO2 NPs using the non-malignant cell line, MDCK. Similar trends and changes in efficacy
with treatment beam energy are shown (Figure 4.12 & 4.13) however, the most noted difference
is the large variations in radiosensitivity observed following a comparison of the cell survival
curves for 9L and MDCK cells. Wason et al (2012) report a selectivity of CeO2 NPs to sen-
sitise malignant pancreatic cancer cells whilst providing radioprotection to the non-malignant
counterpart using 160 kVp X-rays. Interestingly, other research groups have also uncovered a
sensitisation effect with CeO2 NPs at kilovoltage energies [33]. The suggestion of selective be-
haviour is an exciting prospect which should be developed in the near future.
In the development of any new and novel radioprotectors such as CeO2 NPs, it is important to
evaluate its performance against any current “gold standards” that show the best clinical benefits
and are in routine use. Throughout the radiation protection market, the current gold standard
is amifostine. The use of amifostine supports the notion that ideal radioprotectors have a low
effective atomic number (Zamifostine = 11). The added benefit of using low-Z radioprotectors is
that the probability for the production of lethally damaging secondary particle products becomes
less prominent and can be shown by comparing the variation in total cross-sections with atomic
number (Figure 5.2). Future studies should perform parallel experiments, testing the efficacy of
the tested material against amifostine using the same experimental procedures and techniques to
provide first-hand proof of any added benefit that CeO2 NPs may provide.
Chapter 6
Conclusion
The findings reported throughout this study provides a significant contribution to the research
and development of CeO2 NPs in their applications throughout radiotherapy. The structural
and physical characteristics of the synthesised CeO2 NPs are consistent with those published
throughout the literature. Concentration dependent toxicities are evident using two independent
cell lines, further supplementing the current, inconclusive literature pertaining to the toxicity
of CeO2. A threshold of 50 µg/ml was found to be the maximum tolerable concentration that
avoided cytotoxic effects to MDCK and 9L cell lines, with toxicity increasing with increases
in the concentration of the NP. Finally, an energy-dependent efficacy of the material to provide
radiation protection to radioresistant 9L cells is uncovered, with similar indications shown on a
non-malignant MDCK cell line. This study also highlights the importance of considering high-Z
effects and the subsequent influence it can have on the efficacy of a material’s function in the
field of different X-ray energies.
An exciting future exists in the use of CeO2 NPs throughout radiotherapy, where continued de-
velopmental work is bridging the gaps in the knowledge needed for progression to clinical trials.
Future work that will positively contribute to the development of CeO2 as a clinical radioprotec-
tor includes:
• Biocompatibility of CeO2 nanoparticles
Further development of CeO2’s biocompatibility is required to overcome the ambiguity
that surrounds its toxic nature. Concentration dependent toxicities may occur throughout
all biological systems, if so, it could be used to develop concentration limits that mitigate
biological toxicities.
• Testing the efficacy of CeO2 NPs to provide radiation protection to various cell types using
in-vitro and in-vivo models
The range of anatomical locations that CeO2 NPs could be applied to should be compre-
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hensively evaluated. Ideally, no limitation on its clinical radiation protection application
would increase its overall attractiveness and acceptance as a novel radioprotector. Selective
functionality in-vivo could enhance the clinical effectiveness of CeO2 NPs and this should
be investigated.
• Investigate the dynamic valence state using nanoceria with different phases
The dynamic valence state that is responsible for the unique free-radical scavenging ability
of nanoceria should be further developed. Changes in the phase composition and the subse-
quent effect on its scavenging ability can be exploited to develop a synthesising technique
that can optimise the radioprotective abilities of nanoceria.
• Perform parallel studies using amifostine to illustrate the potential benefits CeO2 NPs may
provide
It is important to perform a direct comparison to the “gold standard” radioprotector ami-
fostine. The goal is to demonstrate any clinical radiation protection benefits that CeO2 NPs
may provide as an alternative to amifostine. The acceptance of new techniques requires
strong evidence-based data that show clinical benefits exceeding current practices. Studies
such as direct comparisons may provide this critical information which is currently, to our
knowledge, unavailable.
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Appendix A
Chemical Reagents
GIBCO R©
• Penicillin Streptomycin (Pen Strep)
Mixture contains 5,000 units of penicillin (base) and 5,000 g of streptomycin (base)/ml.
The combination of antibiotics functions to prevent bacterial contamination of cell cultures.
• Trypsin-EDTA (0.05 %) with Phenol Red
Irradiated mixture of proteases derived from porcine pancreas. It is used for adherent cell
dissociation during routine cell culture maintenance.
• Dulbecco’s Modified Eagle Medium (with L-glutamine & Phenol Red)
DMEM is the growth medium supporting the growth of cell cultures. The DMEM is
supplemented with FBS and Pen Strep to provide the ideal medium to support growth.
• Fetal Bovine Serum
Supplement to DMEM to assist in the consistent cell growth over time and passages.
• Phosphate Buffered Saline (with and without Ca & Mg)
Primarily used for washing cells prior to dissociation or staining. The absence of Ca and
Mg functions to rinse chelators prior to cell dissociation.
• Hank’s Balanced Salt Solution (with Phenol Red)
The primary use of HBSS was transporting cell cultures during irradiation processes.
Sigma AldrichTM
• Crystal Violet
Vital stain used to fix and stain cells in-vitro.
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